|Mr. Jerome B. Durso||Pres, CEO & Director||1.16M||N/A||1968|
|Mr. Andrew Saik||Chief Financial Officer||485.07k||N/A||1969|
|Mr. Rocco Venezia||Chief Accounting Officer & Treasurer||660.62k||N/A||1976|
|Mr. Jared M. Freedberg J.D.||Gen. Counsel||691.46k||N/A||1968|
|Dr. M. Michelle Berrey M.D., M.P.H., MPH.||Pres of R&D and Chief Medical Officer||732.13k||N/A||1967|
|Mr. Nareg Sagherian||Exec. Director of Global Investor Relations||N/A||N/A||N/A|
|Mr. David Ford||Chief HR Officer||N/A||N/A||1970|
|Dr. Mark Pruzanski M.D.||Founder, Advisor & Director||N/A||N/A||1968|
|Ms. Linda M. Richardson||Exec. VP & Chief Commercial Officer||N/A||N/A||1964|
|Paul Nitschmann||Sr. VP of Regulatory Affairs||N/A||N/A||N/A|
Intercept Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat progressive non-viral liver diseases in the United States, Europe, and Canada. The company markets Ocaliva, a farnesoid X receptor agonist used for the treatment of primary biliary cholangitis in combination with ursodeoxycholic acid in adults. It is also developing Ocaliva for various indications, including nonalcoholic steatohepatitis; and other product candidates in various stages of clinical and preclinical development. The company has a license agreement with Aralez Pharmaceuticals Canada Inc. to develop and commercialize bezafibrate in the United States. It markets its products through an internal commercial organization and third-party distributors. The company was incorporated in 2002 and is headquartered in New York, New York.
Intercept Pharmaceuticals, Inc.’s ISS governance QualityScore as of 1 September 2022 is 5. The pillar scores are Audit: 9; Board: 3; Shareholder rights: 6; Compensation: 5.